@Gussington did generalise: pre commercialisation, where revenue is less than expenses such as R&D and the like, is always going to be a slow increase in market cap relative to the share price.
Correction: ... is sometimes going to be a slow increase in market cap ...
And sometimes a complete duster, which becomes worthless.
I'm not a particularly insightful investor / stock-watcher, but I can only conclude that in Biotech especially, stocks with merit far outnumber stocks which reach success.
I'm holding a modest parcel, and I've buying in and selling out of this company for years. Not now or ever would I consider it a safe bet, of even avoiding a crash to 25% of current valuation.
Is it worth the risk ...?
Oh, yeah ... sort of. If you like risk.
I don't mind jumping in where fools fear to tread.
In other words, invest in it if you can afford to lose it.
@Gussington did generalise: pre commercialisation, where revenue...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.29 |
Change
-0.010(0.05%) |
Mkt cap ! $408.9M | |||
| Open | High | Low | Value | Volume |
| $21.70 | $21.70 | $21.16 | $147.0K | 6.914K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 47 | $21.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.60 | 300 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$21.19 |
Change
-0.010 ( 0.47 %) |
||||
| Open | High | Low | Volume | ||
| $21.69 | $21.70 | $21.19 | 122 | ||
| Last updated 13.18pm 03/05/2024 ? | |||||
| AVR (ASX) Chart |